Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.71 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 3/20 | 0.54 |
| ▸ | HTR1B | P28222 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3950956 | 1.00 | KCNA3 (0.71) | KCNA3TAAR1ALDH1A1RECQLDRD2 | |
| SCHEMBL311427 | 0.93 | KCNA3 (0.76) | KCNA3TAAR1ALDH1A1RECQLDRD2 | |
| SCHEMBL5375466 | 0.91 | LTA4H (0.68) | KCNA3TAAR1DRD2DRD4DRD3 | |
| SCHEMBL1171574 | 0.91 | KCNA3 (0.73) | KCNA3TAAR1ALDH1A1RECQLDRD2 | |
| SCHEMBL9169690 | 0.91 | KCNA3 (0.73) | KCNA3TAAR1ALDH1A1RECQLDRD2 | |
| SCHEMBL23014989 | 0.91 | KCNA3 (0.73) | KCNA3TAAR1ALDH1A1RECQLDRD2 | |
| SCHEMBL7612512 | 0.91 | KCNA3 (0.73) | KCNA3TAAR1ALDH1A1RECQLDRD2 | |
| SCHEMBL1172113 | 0.91 | KCNA3 (0.73) | KCNA3TAAR1ALDH1A1RECQLDRD2 | |
| SCHEMBL9631165 | 0.91 | KCNA3 (0.73) | KCNA3TAAR1ALDH1A1RECQLDRD2 | |
| SCHEMBL7562039 | 0.91 | KCNA3 (0.73) | KCNA3TAAR1ALDH1A1RECQLDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358908-B2 | Crystals, preparation method and application of a muscarinic receptor antagonist | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2025-07-15 | — | — | US | claimed |
| CN-117105872-A | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2023-11-24 | — | — | CN | claimed |
| US-20230167107-A1 | CRYSTALS, PREPARATION METHOD AND APPLICATION OF A MUSCARINIC RECEPTOR ANTAGONIST | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2023-06-01 | — | — | US | claimed |
| EP-4144733-A1 | CRYSTAL OF M RECEPTOR ANTAGONIST AS WELL AS PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Beijing Showby Pharmaceutical Co., Ltd. (CN) | 2023-03-08 | — | — | EP | claimed |
| CN-115397823-A | M receptor antagonist crystal, preparation method and application thereof | 北京硕佰医药科技有限责任公司 | 2022-11-25 | — | — | CN | claimed |
| CN-111018678-B | Preparation method of high-purity 3-phenoxy bromopropane | 山东省药学科学院 | 2022-08-09 | — | — | CN | claimed |
| CN-113578380-B | Column [5] arene ionic liquid catalyst based on propylimidazole functionalization and preparation method thereof | 抚顺东科新能源科技有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-112645971-B | Method for directly preparing alkyl borate compound from alkyl halide | 中国科学院兰州化学物理研究所 | 2021-12-24 | — | — | CN | claimed |
| CN-113683492-A | Preparation method of 3-phenoxybromopropane or analogue thereof | 常熟理工学院 | 2021-11-23 | — | — | CN | claimed |
| CN-108112252-B | Process for preparing aclidinium bromide | 好利安科技有限公司 | 2020-11-24 | — | — | CN | claimed |
| US-20090299042-A1 | PROCESS FOR MANUFACTURING 3(R)-(2-HYDROXY-2,2-DITHIEN-2-YLACETOXY)-1-(3-PHENOXYPROPYL)-1-AZONIABICYCLO[2.2.2]OCTANE BROMIDE | ALMIRALL, S.A. (ES) | 2009-12-03 | — | — | US | claimed |
| EP-2044067-B1 | PROCESS FOR MANUFACTURING 3(R)-(2-HYDROXY-2,2-DITHIEN-2-YLACETOXY)-1-(3- PHENOXYPROPYL)-1 -AZONIABICYCLO[2.2.2]OCTANE BROMIDE | ALMIRALL SA (ES) | 2009-11-18 | — | — | EP | claimed |
| WO-2009093916-A2 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING AMINOALKANOLS AND THEIR USE | UNIWERSYTET JAGIELLONSKI (PL) | 2009-07-30 | — | — | WO | claimed |
| CN-101490048-A | Process for preparing 3 - (2-hydroxy-2, 2-dithien-2-ylacetoxy) -1- (3-phenoxypropyl) -1-azoniabicyclo [2.2.2] octane bromide | ALMIRALL LAB (ES) | 2009-07-22 | — | — | CN | claimed |
| EP-2044067-A1 | PROCESS FOR MANUFACTURING 3(R)-(2-HYDROXY-2,2-DITHIEN-2-YLACETOXY)-1-(3- PHENOXYPROPYL)-1 -AZONIABICYCLO[2.2.2]OCTANE BROMIDE | Laboratorios Almirall, S.A. (ES) | 2009-04-08 | — | — | EP | claimed |
| WO-2008009397-A1 | PROCESS FOR MANUFACTURING 3(R)-(2-HYDROXY-2,2-DITHIEN-2-YLACETOXY)-1-(3-PHENOXYPROPYL)-1-AZONIABICYCLO[2.2.2]OCTANE BROMIDE | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-01-24 | — | — | WO | claimed |
| US-7296576-B2 | Polymers for enhanced solubility of nanomaterials, compositions and methods therefor | ZYVEX PERFORMANCE MATERIALS, LLC (US) | 2007-11-20 | — | — | US | claimed |
| US-20060041104-A1 | Polymers for enhanced solubility of nanomaterials, compositions and methods therefor | ZYVEX CORPORATION (US) | 2006-02-23 | — | — | US | claimed |
| WO-2005073709-A1 | DETERMINATION OF THE OPERATIONAL ISOELECTRIC POINT OF ISOELECTRIC MEMBRANES | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2005-08-11 | — | — | WO | claimed |
| US-5380910-A | Dehalogeno coupling | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-01-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167107-A1 | CRYSTALS, PREPARATION METHOD AND APPLICATION OF A MUSCARINIC RECEPTOR ANTAGONIST | CHRM5, CHRM2, CHRM3 | KCNA3 86/4885TAAR1 159/4885ALDH1A1 4300/4885 |
| US-12358908-B2 | Crystals, preparation method and application of a muscarinic receptor antagonist | CHRM5, CHRM2, CHRM3 | KCNA3 86/4885TAAR1 159/4885ALDH1A1 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.